All‐cause mortality · adults and children with initial sepsis and septic shocka
Liberal initial fluid probably leads to higher all‐cause mortality compared with conservative fluid therapy (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality · patients with solid tumours without thrombocytopenia before chemotherapy
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review
All‐cause mortality · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
1 finding from 1 review
no estimate extracted
4 participants
GRADE not reported
All‐cause mortality · people with cardiac channelopathies
Implantable cardioverter defibrillators may leads to lower all‐cause mortality compared with β‐blocker therapy (low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).
1 finding from 1 review
Mortality within the longest · adults undergoing non‐cardiac surgery
Continuation showed no clear difference in all‐cause mortality (at longest compared with discontinuation of antiplatelet therapy (low certainty).
1 finding from 1 review
All‐cause mortality ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All‐cause mortality ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (up to 30 days) · adults undergoing non‐cardiac surgery
Continuation showed no clear difference in all‐cause mortality (up to 30 days) compared with discontinuation of antiplatelet therapy (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
It is very uncertain whether the intervention changes all‐cause mortality at 31 to 100 days (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at 31 to 100 days · Adults with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem…
1 finding from 1 review
All‐cause mortality · adults with growth‐hormone secreting pituitary adenomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults with growth‐hormone secreting pituitary adenomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with heart failure
Coenzyme Q10 probably leads to lower all‐cause mortality compared with placebo or conventional therapy (moderate certainty).
1 finding from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Idraparinux showed no clear difference in all‐cause mortality compared with standard therapy (low certainty).
1 finding from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in all‐cause mortality compared with standard therapy (moderate certainty).
1 finding from 1 review
All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
self‐management of oral anticoagulation probably leads to lower all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring or self‐management of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review
All‐cause mortality · Patients on long‐term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment
Self‐monitoring of oral anticoagulation showed no clear difference in all‐cause mortality compared with standard care (moderate certainty).
1 finding from 1 review